ArticleNature communications2024

An in situ depot for the sustained release of a TLR7/8 agonist in combination with a TGFβ inhibitor promotes anti-tumor immune responses.

Sophie B Jensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.